Pharming Group (NASDAQ:PHGUF) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Zacks has also given Pharming Group an industry rank of 100 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research lowered Pharming Group from a “buy” rating to a “hold” rating in a research report on Friday, November 4th.

Pharming Group (NASDAQ:PHGUF) opened at 0.36 on Tuesday. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.37. The stock’s 50 day moving average price is $0.00 and its 200 day moving average price is $0.00. The firm’s market cap is $148.54 million.

“Zacks: Pharming Group (PHGUF) Receives Average Recommendation of “Strong Buy” from Analysts” was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at http://www.dailypolitical.com/2017/02/16/zacks-pharming-group-phguf-receives-average-recommendation-of-strong-buy-from-analysts.html.

About Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

5 Day Chart for NASDAQ:PHGUF

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.